What is OS Therapies's stock issuance proceeds?

OS Therapies (OSTX) reported stock issuance proceeds of $1.05M in Q3 2025.

What does stock issuance proceeds mean?

The total cash inflows received from the sale of common equity shares to investors. This metric is a primary indicator of the company's ability to raise capital to fund ongoing operations and clinical trials.

OS Therapies OSTX Stock Issuance Proceeds

Stock Issuance Proceeds at other companies

CTO

Citius Oncology, Inc.CTOR

$15.13M—

Other financials

Income statement

See full

Operating income-$10.2M-103%

Net income-$10.4M-168%

EPS (diluted)-$0.27-50.0%

Balance sheet

See full

Cash & equivalents$917.6K-69.1%

Total debt$20.0M—

Total equity-$10.8M-159%

Total assets$7.3M+71.7%

Cash flow

See full

Operating cash flow-$4.6M-32.6%

CapEx$316.4K—

Free cash flow-$3.7M—

Valuation

See full

Market cap$84.62M+65.5%

Enterprise value$103.7M—

Returns & leverage

See full

Return on equity470%—

Debt / equity-1.8×—

Current ratio0.1×-1.1×

Where this comes from

Reported directly by OS Therapies in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfCommonStock.

The official record: OS Therapies’s 10-Q, filed November 14, 2025, on SEC EDGAR. View the filing →

Ask your AI about OS Therapies's stock issuance proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is OS Therapies's stock issuance proceeds?: OS Therapies (OSTX) reported stock issuance proceeds of $1.05M in Q3 2025.
What does stock issuance proceeds mean?: The total cash inflows received from the sale of common equity shares to investors. This metric is a primary indicator of the company's ability to raise capital to fund ongoing operations and clinical trials.